Freshly Printed - allow 7 days lead
Couldn't load pickup availability
Blood and Marrow Transplantation Long Term Management
Survivorship after Transplant
Bipin N. Savani (Edited by), Andre Tichelli (Edited by)
9781119612698, Wiley
Hardback, published 3 June 2021
464 pages
27.4 x 22.2 x 2.8 cm, 1.497 kg
Blood and Marrow Transplantation Long Term Management Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients. The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated. These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality. Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.
Foreword by Professor John Barrett vii Foreword by Professor John Goldman viii List of Contributors ix Section 1 Late effects concepts 1 1 Introduction to long‐term survivorship after hematopoietic cell transplantation 3 2 International Blood and Marrow Registries: trends on long‐term data collection 6 3 Long‐term follow‐up program and transplant clinic setup 14 4 Telemedicine in patient care of long‐term transplant survivors 25 5 Long‐term follow‐up calendar 33 6 Late effects post‐allogeneic hematopoietic stem cell transplantation 38 7 Late effects post‐autologous hematopoietic stem cell transplantation 47 8 Long‐term follow‐up of children 58 9 Graft‐versus‐host disease and late effects after hematopoietic stem cell transplantation 73 10 Screening and prevention guidelines for hematopoietic cell transplant survivors 80 11 Biology of survivorship after blood or marrow transplantation 92 Section 2 Specific late effects 101 12 Second malignancies 103 13 Anti‐infective prophylaxis, immunization and prevention of late infectious complications 112 14 Seasonal respiratory viral infections 119 15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation 132 16 Skin chronic GVHD 140 17 Ocular complications 166 18 Management of oral and dental complications 176 19 Thyroid disease: monitoring and management guidelines 183 20 Pretransplant considerations in gender, reproductive, and sexual health 189 21 Posttransplant Considerations in Gender, Reproductive, and Sexual Health 198 22 Fertility issues, fertility preservation, and pregnancy outcome in long‐term survivors 211 23 Sexual Dysfunction in Long‐Term Survivors 221 24 Late non‐infectious pulmonary complications 231 25 Cardiac and arterial complications 241 26 Cardiovascular risk factors 251 27 Gastrointestinal complications 260 28 Hepatic Complications 271 29 Renal complications 278 30 Posttransplantation bone disease: prevalence, surveillance, prevention, and management 287 31 Late neurologic complications 300 32 Neurocognitive dysfunction 312 33 Psychological Distress 330 34 Evaluation and management of fatigue in survivors of allogeneic hematopoietic stem cell transplantation 337 35 Social Issues 349 36 Health‐related quality of life in adult and pediatric survivors 355 Section 3 Supportive care and patients reported outcomes 381 37 Immunosuppressive agents and monitoring in long‐term survivors 383 38 Nutritional support and nutritional supplementation 393 39 Daily routines and healthy lifestyle guidelines 397 40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges 402 41 Complementary and alternative medicine in HSCT 406 42 Impact of adherence in outcome of long‐term survivors 413 43 Prominent role of allied health professionals 418 44 Patient reported outcomes 420 45 Caregivers of long‐term survivors 428 46 Patient’s perspective: memoir of a recovered lymphomaniac 434 Appendix 1 Commonly used transplant‐related medications in long‐term survivors 442 Appendix 2 The eGVHD App 445 Index 448
Bipin N. Savani and André Tichelli
Rachel Phelan, Jakob R. Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen E. Shaw
André Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rovó
Catherine J. Lee, Mihkaila Wickline, and Mary E.D. Flowers
André Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rovó
Shahrukh K. Hashmi and Yoshihiro Inamoto
Rajshekhar Chakraborty and Betty K. Hamilton
Paul A. Carpenter
David Michonneau, Aurélien Sutra del Galy, and Gérard Socié
Neel S. Bhatt, J. Douglas Rizzo, and Navneet S. Majhail
Smita Bhatia
Aurélien Sutra del Galy, David Michonneau, and Gérard Socié
Per Ljungman
Nosha Farhadfar, Zeina Al‐Mansour, and John R. Wingard
Enric Carreras and Montserrat Rovira
Attilio Olivieri, Anna Campanati, Gaia Goteri, and Andrea Bacigalupo
Alicia Rovó, André Tichelli, and Yoshihiro Inamoto
Hildegard T. Greinix
Juliana Matthews, Leslee Matheny, and Shubhuda Jagasia
Dana Shanis, Jeanne Murphy, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton
Jeanne Murphy, Dana Shanis, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton
Alicia Rovó, Alison W. Loren, André Tichelli, and Nina Salooja
Rebecca L. Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Nathan
Ayman O. Soubani
Alicia Rovó and André Tichelli
Kimberley Doucette and Minoo Battiwalla
Sumona Bhattacharya, Steven Pavletic, and Theo Heller
Christy Ann L. Gilman, Christopher Koh, Steven Pavletic, and Theo Heller
Insara Jaffer Sathick and Sangeeta Hingorani
Christine N. Duncan
Enrico Maffini
David Buchbinder and Angela Scherwath
Anna Barata, Aasha I. Hoogland, and Heather S. L. Jim
Sandra A. Mitchell
Sanghee Hong and Navneet S. Majhail
Sandra A. Mitchell, Lori Wiener, Jenny Hoag, Abigail Fry, and Margaret F. Bevans
Kathryn A. Culos and Katie S. Gatwood
Shigeo Fuji
Melissa Logue
Katrina M. Stokes
Ibrahim N. Muhsen, Bipin N. Savani,, and Shahrukh K. Hashmi
Corien Eeltink and Annika Kisch
Catherine E. Lucid
Hélène Schoemans
Angela Moreschi Woods
Michael Brown
Kathryn A. Culos and Katie S. Gatwood
Hélène Schoemans
Subject Areas: Clinical & internal medicine [MJ]
